HPV vaccine may be cost-effective strategy for preventing oropharyngeal cancer in males
the ONA take:
According to a new study published online early in the journal Cancer, researchers from Princess Margaret Cancer Centre in Toronto, Ontario, Canada, have found that vaccinating adolescent boys against the human papillomavirus (HPV) may be a cost-effective approach for preventing squamous cell oropharyngeal cancer.
For the study, researchers applied a statistical model to a population of over 190,000 Canadian boys who were 12 years old in 2012. Results showed that the HPV vaccination could save $8 million to $28 million Canadian dollars over the boys' lifetimes.
The findings of this study are important because HPV-related oropharygneal cancer is projected to become the most common HPV-related cancer in the United States by 2020.
The authors of the study hope that the findings of this study will increase public awareness and persuade policymakers across the world to fund the HPV vaccination in boys.
HPV vaccinations, such as Gardasil, are known to be effective at reducing the risk of cervical, vulvar, vaginal, and anal cancer in females, and anal cancer in males.
HPV vaccine may be a cost-effective approach for preventing squamous cell oropharyngeal cancer.
- Study Identifies Factors Associated With Hearing Loss in Polycythemia Vera
- Ezh2 Inhibitors May Offer Cure for Chronic Myelogenous Leukemia
- Ruxolitinib: A Targeted Treatment Option for Patients with Polycythemia Vera
- Incontinence Affects QOL for Survivors of Gynecologic Cancers
- Robotic Surgery Provides Good Outcomes and Survival in Oropharyngeal Cancer
- Overall Benefits of Vaporized Nicotine Products Outweigh Harms, Says International Panel of Experts
- Sugar and Cancer: Mitigating the Affects of Diet on Cancer
- Nurse Residency Programs Can Impact Oncology Nursing Practice, Outcomes
- Tumor Markers (Fact Sheet)
- Implementing a Distress Screening Process for Cancer Patients
- SBRT Improves Overall and Disease-Specific Survival in Stage I NSCLC
- Patients Receiving RT in APBI Facilities Despite Eligibility for Observation
- Prolonged Imatinib Therapy Improves Likelihood of Deeper Molecular Response
- ASCO, ASTRO Issue Guideline Update for Postmastectomy RT
- Study Assesses Efficacy of Ramucirumab in HCC by Child-Pugh Score
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|